JPM22

Biotech By Damian Garde and Adam Feuerstein

Biogen CEO: Company was ‘wrong’ about initial Aduhelm price, ‘courageous’ to lower it

Biotech By Adam Feuerstein

FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T treatment

Biotech By Matthew Herper and Megan Molteni

Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions

Biotech By Matthew Herper and Megan Molteni

Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research

Don't Miss By STAT Staff

A preview of the burning biotech and health tech questions at JPM 2022

First Opinion By Dan Michelson

Covid-19 is no longer the biggest issue facing hospitals. Staffing is

Biotech By Angus Chen

A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies

Health Tech By Mohana Ravindranath

Telehealth companies are testing the waters with taking on more risk